Characterization of Shiga toxin-producing Escherichia coli strains isolated from human patients in Germany over a 3-year period.
We have investigated 677 Shiga toxin-producing Escherichia coli (STEC) strains from humans to determine their serotypes, virulence genes, and clinical signs in patients. Six different Shiga toxin types (1, 1c, 2, 2c, 2d, and 2e) were distributed in the STEC strains. Intimin (eae) genes were present in 62.6% of the strains and subtyped into intimins alpha1, beta1, gamma1, epsilon, theta, and eta. Shiga toxin types 1c and 2d were present only in eae-negative STEC strains, and type 2 was significantly (P < 0.001) more frequent in eae-positive STEC strains. Enterohemorrhagic E. coli hemolysin was associated with 96.2% of the eae-positive strains and with 65.2% of the eae-negative strains. Clinical signs in the patients were abdominal pain (8.7%), nonbloody diarrhea (59.2%), bloody diarrhea (14.3%), and hemolytic-uremic syndrome (HUS) (3.5%), and 14.3% of the patients had no signs of gastrointestinal disease or HUS. Infections with eae-positive STEC were significantly (P < 0.001) more frequent in children under 6 years of age than in other age groups, whereas eae-negative STEC infections dominated in adults. The STEC strains were grouped into 74 O:H types by serotyping and by PCR typing of the flagellar (fliC) genes in 221 nonmotile STEC strains. Eleven serotypes (O157:[H7], O26:[H11], O103:H2, O91:[H14], O111:[H8], O145:[H28], O128:H2, O113:[H4], O146:H21, O118:H16, and O76:[H19]) accounted for 69% of all STEC strains. We identified 41 STEC strains belonging to 31 serotypes which had not previously been described as human STEC. Twenty-six of these were positive for intimins alpha1 (one serotype), beta1 (eight serotypes), epsilon (two serotypes), and eta (three serotypes). Our study indicates that different types of STEC strains predominate in infant and adult patients and that new types of STEC strains are present among human isolates.
Beutin
Lothar
L
Division of Microbial Toxins, Department of Biological Safety, Robert Koch Institute, D-13353 Berlin, Germany. BeutinL@rki.de
Krause
Gladys
G
Zimmermann
Sonja
S
Kaulfuss
Stefan
S
Gleier
Kerstin
K
D018829:Adhesins, Bacterial / Q000235:genetics; D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D000942:Antigens, Bacterial / Q000302:isolation & purification; D002352:Carrier Proteins / Q000235:genetics; D002648:Child; D002675:Child, Preschool; D003967:Diarrhea / Q000382:microbiology; D004926:Escherichia coli / Q000145:classification / Q000235:genetics / Q000302:isolation & purification / Q000472:pathogenicity*; D004927:Escherichia coli Infections / Q000453:epidemiology / Q000382:microbiology*; D029968:Escherichia coli Proteins; D005858:Germany / Q000453:epidemiology; D006461:Hemolysis; D006801:Humans; D007223:Infant; D008875:Middle Aged; D010146:Pain / Q000382:microbiology; D010641:Phenotype; D012703:Serotyping; D022603:Shiga Toxins / Q000737:chemistry* / Q000302:isolation & purification
D018829:Adhesins, Bacterial; D000942:Antigens, Bacterial; D002352:Carrier Proteins; D029968:Escherichia coli Proteins; D022603:Shiga Toxins; C073819:eaeA protein, E coli